The two facets of gp130 signalling in liver tumorigenesis

Dirk Schmidt-Arras*, Eithan Galun*, Stefan Rose-John*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

The liver is a vital organ with multiple functions and a large regenerative capacity. Tumours of the liver are the second most frequently cause of cancer-related death and develop in chronically inflamed livers. IL-6-type cytokines are mediators of inflammation and almost all members signal via the receptor subunit gp130 and the downstream signalling molecule STAT3. We here summarize current knowledge on how gp130 signalling and STAT3 in tumour cells and cells of the tumour micro-environment drives hepatic tumorigenesis. We furthermore discuss very recent findings describing also anti-tumorigenic roles of gp130/STAT3 and important considerations for therapeutic interventions.

Original languageAmerican English
Pages (from-to)609-624
Number of pages16
JournalSeminars in Immunopathology
Volume43
Issue number4
DOIs
StatePublished - Aug 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Keywords

  • Anti-tumour immunity
  • Cholangiocarcinoma (CCA)
  • Hepatocellular carcinoma (HCC)
  • IL-6
  • Inflammation
  • STAT3
  • Tumour micro-environment
  • gp130

Fingerprint

Dive into the research topics of 'The two facets of gp130 signalling in liver tumorigenesis'. Together they form a unique fingerprint.

Cite this